$22.81
1.21% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US3723032062
Symbol
GMAB

Genmab - ADR Stock price

$22.82
+3.51 18.18% 1M
+2.65 13.14% 6M
+1.95 9.34% YTD
-3.59 13.59% 1Y
-8.29 26.65% 5Y
+13.96 157.47% 10Y
+19.05 504.98% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.27 1.17%
ISIN
US3723032062
Symbol
GMAB
Sector

Key metrics

Market capitalization $14.13b
Enterprise Value $13.65b
P/E (TTM) P/E ratio 3.95
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.10
P/S ratio (TTM) P/S ratio 11.49
P/B ratio (TTM) P/B ratio 1.76
Revenue growth (TTM) Revenue growth -55.29%
Revenue (TTM) Revenue $1.23b
EBIT (operating result TTM) EBIT $383.59m
Free Cash Flow (TTM) Free Cash Flow $-13.99m
Cash position $499.52m
EPS (TTM) EPS $5.77
P/E forward 14.86
P/S forward 3.95
EV/Sales forward 3.82
Short interest 0.40%
Show more

Is Genmab - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Genmab - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Genmab - ADR forecast:

17x Buy
71%
6x Hold
25%
1x Sell
4%

Analyst Opinions

24 Analysts have issued a Genmab - ADR forecast:

Buy
71%
Hold
25%
Sell
4%

Financial data from Genmab - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,230 1,230
55% 55%
100%
- Direct Costs 50 50
21% 21%
4%
1,179 1,179
42% 42%
96%
- Selling and Administrative Expenses 208 208
61% 61%
17%
- Research and Development Expense 560 560
56% 56%
46%
396 396
-
32%
- Depreciation and Amortization 12 12
-
1%
EBIT (Operating Income) EBIT 384 384
56% 56%
31%
Net Profit 369 369
56% 56%
30%

In millions USD.

Don't miss a Thing! We will send you all news about Genmab - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genmab - ADR Stock News

Neutral
GlobeNewsWire
2 days ago
Company Announcement COPENHAGEN, Denmark; June 12, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 3,320 restricted stock units and 3,636 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally ...
Neutral
GlobeNewsWire
4 days ago
Company Announcement COPENHAGEN, Denmark; June 10, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
Neutral
The Motley Fool
12 days ago
On a generally upbeat Monday for the stock market, investors weren't only buying into U.S. companies. Quite a few of them also piled into the American Depositary Receipts (ADRs) of Danish biotech Genmab (GMAB 3.94%), on the back of encouraging news from the laboratory.
More Genmab - ADR News

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,682
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today